83 FR 29125 - National Institute on Drug Abuse; Notice of Closed Meetings
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health Federal Register Volume 83, Issue 121 (June 22, 2018)
National Institutes of Health
Federal Register Volume 83, Issue 121 (June 22, 2018)
| Page Range | 29125-29126 | |
| FR Document | 2018-13417 |
[Federal Register Volume 83, Number 121 (Friday, June 22, 2018)] [Notices] [Pages 29125-29126] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2018-13417] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional). Date: June 29, 2018. Time: 8:00 a.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301-827-5820, [email protected]. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Multi-site Clinical Trials. Date: July 26-27, 2018. Time: 10:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting). Contact Person: Susan O. McGuire, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Blvd., Room 4245, Rockville, MD 20852, (301) 827-5817, [email protected]. (Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) [[Page 29126]] Dated: June 19, 2018. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018-13417 Filed 6-21-18; 8:45 am] BILLING CODE 4140-01-P
![Federal Register / Vol. 83, No. 121 / Friday, June 22, 2018 / Notices 29125
forthcoming public advisory committee location of the advisory committee DEPARTMENT OF HEALTH AND
meeting of the Tobacco Products meeting, and the background material HUMAN SERVICES
Scientific Advisory Committee. The will be posted on FDA’s website after
general function of the committee is to the meeting. Background material is National Institutes of Health
provide advice and recommendations to available at https://www.fda.gov/
the Agency on FDA’s regulatory issues. AdvisoryCommittees/Calendar/ National Institute on Drug Abuse;
The meeting will be open to the public. default.htm. Scroll down to the Notice of Closed Meetings
DATES: The meeting will be held on appropriate advisory committee meeting
link. Pursuant to section 10(d) of the
September 13, 2018, from 8:30 a.m. to
Procedure: Interested persons may Federal Advisory Committee Act, as
5 p.m. and on September 14, 2018, from
present data, information, or views, amended, notice is hereby given of the
8 a.m. to 3 p.m.
orally or in writing, on issues pending following meetings.
ADDRESSES: FDA White Oak Conference
Center, 10903 New Hampshire Ave., before the committee. Written The meetings will be closed to the
Bldg. 31 Conference Center, the Great submissions may be made to the contact public in accordance with the
Room (Rm. 1503), Silver Spring, MD person on or before August 29, 2018. provisions set forth in sections
20993–0002. Answers to commonly Oral presentations from the public will 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
asked questions including information be scheduled between approximately 8 as amended. The grant applications and
regarding special accommodations due a.m. and 9 a.m. on September 14, 2018. the discussions could disclose
to a disability, visitor parking, and Those individuals interested in making confidential trade secrets or commercial
transportation may be accessed at: formal oral presentations should notify property such as patentable material,
https://www.fda.gov/Advisory the contact person and submit a brief and personal information concerning
Committees/AboutAdvisoryCommittees/ statement of the general nature of the individuals associated with the grant
ucm408555.htm. evidence or arguments they wish to applications, the disclosure of which
present, the names and addresses of would constitute a clearly unwarranted
FOR FURTHER INFORMATION CONTACT: invasion of personal privacy.
proposed participants, and an
Caryn Cohen, Office of Science, Center indication of the approximate time
for Tobacco Products, Food and Drug Name of Committee: National Institute on
requested to make their presentation on Drug Abuse Special Emphasis Panel;
Administration, Document Control or before August 16, 2018. Time allotted Mechanism for Time-Sensitive Drug Abuse
Center, 10903 New Hampshire Ave., for each presentation may be limited. If Research (R21 Clinical Trial Optional).
Bldg. 71, Rm. G335, Silver Spring, MD the number of registrants requesting to Date: June 29, 2018.
20993–0002, 1–877–287–1373, email: speak is greater than can be reasonably Time: 8:00 a.m. to 2:00 p.m.
TPSAC@fda.hhs.gov, or FDA Advisory accommodated during the scheduled Agenda: To review and evaluate grant
Committee Information Line, 1–800– open public hearing session, FDA may applications.
741–8138 (301–443–0572 in the conduct a lottery to determine the Place: National Institutes of Health,
Washington, DC area). A notice in the speakers for the scheduled open public Neuroscience Center, 6001 Executive
Federal Register about last minute hearing session. The contact person will Boulevard, Rockville, MD 20852 (Telephone
modifications that impact a previously notify interested persons regarding their Conference Call).
announced advisory committee meeting request to speak by August 17, 2018.
Contact Person: Hiromi Ono, Ph.D.,
cannot always be published quickly Scientific Review Officer, Office of
Persons attending FDA’s advisory Extramural Policy and Review, National
enough to provide timely notice.
committee meetings are advised that the Institute on Drug Abuse, National Institutes
Therefore, you should always check the
Agency is not responsible for providing of Health, DHHS, 6001 Executive Boulevard,
Agency’s website at https://
access to electrical outlets. Room 4238, MSC 9550, Bethesda, MD 20892,
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the FDA welcomes the attendance of the 301–827–5820, hiromi.ono@nih.gov.
appropriate advisory committee meeting public at its advisory committee This notice is being published less than 15
link, or call the advisory committee meetings and will make every effort to days prior to the meeting due to the timing
information line to learn about possible accommodate persons with disabilities. limitations imposed by the review and
modifications before coming to the If you require accommodations due to a funding cycle.
meeting. disability, please contact Caryn Cohen Name of Committee: National Institute on
at least 7 days in advance of the meeting Drug Abuse Special Emphasis Panel; Multi-
SUPPLEMENTARY INFORMATION: (see, FOR FURTHER INFORMATION site Clinical Trials.
Agenda: On September 13 and 14, CONTACT). Date: July 26–27, 2018.
2018, the Committee will discuss FDA is committed to the orderly Time: 10:00 a.m. to 8:00 p.m.
modified risk tobacco product conduct of its advisory committee Agenda: To review and evaluate grant
applications, submitted by R.J. Reynolds meetings. Please visit our applications.
Tobacco Company for six products: website at https://www.fda.gov/ Place: National Institutes of Health,
• MR0000068: Camel Snus Frost AdvisoryCommittees/AboutAdvisory
Neuroscience Center, 6001 Executive
• MR0000069: Camel Snus Frost Large Committees/ucm111462.htm for
Boulevard, Rockville, MD 20852 (Virtual
• MR0000070: Camel Snus Mellow Meeting).
procedures on public conduct during Contact Person: Susan O. McGuire, Ph.D.,
• MR0000071: Camel Snus Mint advisory committee meetings. Scientific Review Officer, Office of
• MR0000072: Camel Snus Robust Notice of this meeting is given under Extramural Policy and Review, National
• MR0000073: Camel Snus Winterchill
the Federal Advisory Committee Act Institute on Drug Abuse, National Institutes
daltland on DSKBBV9HB2PROD with NOTICES
FDA intends to make background (5 U.S.C. app. 2). of Health, DHHS, 6001 Executive Blvd.,
material available to the public no later Room 4245, Rockville, MD 20852, (301) 827–
Dated: June 18, 2018.
than 2 business days before the meeting. 5817, mcguireso@mail.nih.gov.
If FDA is unable to post the background Leslie Kux,
(Catalogue of Federal Domestic Assistance
material on its website prior to the Associate Commissioner for Policy. Program Nos.: 93.279, Drug Abuse and
meeting, the background material will [FR Doc. 2018–13405 Filed 6–21–18; 8:45 am] Addiction Research Programs, National
be made publicly available at the BILLING CODE 4164–01–P Institutes of Health, HHS)
VerDate Sep<11>2014 17:16 Jun 21, 2018 Jkt 244001 PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 E:\FR\FM\22JNN1.SGM 22JNN1](https://thefederalregister.org/doc/83_FR_29246/page/1.svg)
![29126 Federal Register / Vol. 83, No. 121 / Friday, June 22, 2018 / Notices
Dated: June 19, 2018. DEPARTMENT OF HEALTH AND Contact Person: Priti Mehrotra, Ph.D.,
Natasha M. Copeland, HUMAN SERVICES Chief, Immunology Review Branch, Scientific
Review Program, Division of Extramural
Program Analyst, Office of Federal Advisory Activities, Room #3G40, National Institutes
Committee Policy. National Institutes of Health
of Health/NIAID, 5601 Fishers Lane, MSC
[FR Doc. 2018–13417 Filed 6–21–18; 8:45 am] 9823, Bethesda, MD 20892–7616, 240–669–
National Institute of Allergy and
BILLING CODE 4140–01–P 5066, pmehrotra@niaid.nih.gov.
Infectious Diseases; Notice of Closed
Meetings (Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
DEPARTMENT OF HEALTH AND Pursuant to section 10(d) of the and Transplantation Research; 93.856,
HUMAN SERVICES Federal Advisory Committee Act, as Microbiology and Infectious Diseases
amended, notice is hereby given of the Research, National Institutes of Health, HHS)
National Institutes of Health following meetings. Dated: June 19, 2018.
The meetings will be closed to the
Natasha M. Copeland,
National Institute of Allergy and public in accordance with the
Infectious Diseases; Notice of Closed provisions set forth in sections Program Analyst, Office of Federal Advisory
Committee Policy.
Meeting 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and [FR Doc. 2018–13414 Filed 6–21–18; 8:45 am]
Pursuant to section 10(d) of the the discussions could disclose BILLING CODE 4140–01–P
Federal Advisory Committee Act, as confidential trade secrets or commercial
amended, notice is hereby given of the property such as patentable material,
following meeting. and personal information concerning DEPARTMENT OF HEALTH AND
individuals associated with the grant HUMAN SERVICES
The meeting will be closed to the
public in accordance with the applications, the disclosure of which National Institutes of Health
provisions set forth in sections would constitute a clearly unwarranted
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., invasion of personal privacy. Office of the Director, National
as amended. The contract proposals and Name of Committee: National Institute of Institutes of Health; Notice of Meeting
the discussions could disclose Allergy and Infectious Diseases, Special
Pursuant to section 10(a) of the
confidential trade secrets or commercial Emphasis Panel, Integrated Preclinical/
Clinical AIDS Vaccine Development Federal Advisory Committee Act, as
property such as patentable material, amended (5 U.S.C. App.), notice is
Program, (IPCAVD) (U19).
and personal information concerning hereby given of a meeting of the Office
Date: July 12–13, 2018.
individuals associated with the contract Time: 9:00 a.m. to 5:00 p.m. of AIDS Research Advisory Council.
proposals, the disclosure of which Agenda: To review and evaluate grant The meeting will be open to the
would constitute a clearly unwarranted applications. public, with attendance limited to space
invasion of personal privacy. Place: National Institutes of Health, 5601 available. Individuals who plan to
Fishers Lane, Rockville, MD 20892
Name of Committee: National Institute of (Telephone Conference Call). attend and need special assistance, such
Allergy and Infectious Diseases Special Contact Person: J. Bruce Sundstrom, Ph.D., as sign language interpretation or other
Emphasis Panel; Source Selection Meeting Scientific Review Officer, Scientific Review reasonable accommodations, should
for NIAID IRF at Fort Detrick. Program, Division of Extramural Activities, notify the Contact Person listed below
Date: July 3, 2018. Room 3G11A, National Institutes of Health/ in advance of the meeting.
Time: 1:00 p.m. to 3:00 p.m. NIAID, 5601 Fishers Lane, MSC 9823,
Bethesda, MD 20892–9823, 240–669–5045, Name of Committee: Office of AIDS
Agenda: To review and evaluate contract Research Advisory Council.
proposals. sundstromj@niaid.nih.gov.
Date: July 12, 2018.
Place: National Institutes of Health, 5601 Name of Committee: National Institute of Time: 11:00 a.m. to 12:30 p.m.
Fishers Lane, Rockville, MD 20892 Allergy and Infectious Diseases Special Agenda: Report to the OAR Director;
(Telephone Conference Call). Emphasis Panel, NIAID Investigator Initiated Overview of key upcoming OAR activities;
Program Project Applications (P01). Updates of the HHS HIV/AIDS Treatment
Contact Person: Dharmendar Rathore,
Date: July 12, 2018. and Prevention Guidelines.
Ph.D., Senior Scientific Review Officer, Time: 1:00 p.m. to 6:00 p.m.
Scientific Review Program, Division of Place: National Institutes of Health, 5601
Agenda: To review and evaluate grant
Extramural Activities, Room 3G30, National Fishers Lane, Bethesda, MD 20892 (Virtual
applications.
Institutes of Health/NIAID, 5601 Fishers Meeting).
Place: National Institutes of Health, 5601
Contact Person: Paul A. Sato, Medical
Lane, MSC 9834, Bethesda, MD 20892–9834, Fishers Lane, Rockville, MD 20892
Officer, Office of AIDS Research, Office of the
240–669–5058, rathored@mail.nih.gov. (Telephone Conference Call).
Director, NIH, 5601 Fishers Lane, Room 2E62
This notice is being published less than 15 Contact Person: Priti Mehrotra, Ph.D.,
Rockville, MD 20852, 240–480–2330,
Chief, Immunology Review Branch, Scientific
days prior to the meeting due to the urgent paul.sato@nih.gov.
Review Program, Division of Extramural
need to meet timing limitations imposed by Activities, Room #3G40, National Institutes Any interested participants are encouraged
the intramural research review cycle. of Health/NIAID, 5601 Fishers Lane, MSC to join this meeting at the weblink provided,
(Catalogue of Federal Domestic Assistance 9823, Bethesda, MD 20892–7616, 240–669– at least 30 minutes prior to the scheduled
Program Nos. 93.855, Allergy, Immunology, 5066, pmehrotra@niaid.nih.gov. start time. Information is also available on
and Transplantation Research; 93.856, Name of Committee: National Institute of the Institute’s/Center’s home page:
Allergy and Infectious Diseases Special www.oar.nih.gov, where an agenda and any
Microbiology and Infectious Diseases
Emphasis Panel, NIAID Investigator Initiated additional information for the meeting will
Research, National Institutes of Health, HHS)
daltland on DSKBBV9HB2PROD with NOTICES
Program Project Applications (P01). be posted when available.
Dated: June 19, 2018. Date: July 13, 2018. (Catalogue of Federal Domestic Assistance
Natasha M. Copeland, Time: 10:00 a.m. to 5:00 p.m. Program Nos. 93.14, Intramural Research
Agenda: To review and evaluate grant Training Award; 93.22, Clinical Research
Program Analyst, Office of Federal Advisory
applications. Loan Repayment Program for Individuals
Committee Policy.
Place: National Institutes of Health, 5601 from Disadvantaged Backgrounds; 93.232,
[FR Doc. 2018–13415 Filed 6–21–18; 8:45 am] Fishers Lane, Rockville, MD 20892 Loan Repayment Program for Research
BILLING CODE 4140–01–P (Telephone Conference Call). Generally; 93.39, Academic Research
VerDate Sep<11>2014 17:16 Jun 21, 2018 Jkt 244001 PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 E:\FR\FM\22JNN1.SGM 22JNN1](https://thefederalregister.org/doc/83_FR_29246/page/2.svg)
Document Created: 2018-11-06 09:51:16
Document Modified: 2018-11-06 09:51:16
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Dates | June 29, 2018. | |
| FR Citation | 83 FR 29125 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR